A detailed history of Israel Englander (Millennium Management LLC) transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 10,300 shares of RVNC stock, worth $26,471. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,300
Previous 756,912 98.64%
Holding current value
$26,471
Previous $1.95 Million 98.66%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.57 - $2.57 $1.57 Million - $1.57 Million
-609,102 Reduced 80.47%
147,810 $379,000
Q2 2024

Aug 14, 2024

BUY
$2.34 - $4.73 $1.41 Million - $2.86 Million
604,547 Added 396.78%
756,912 $1.95 Million
Q1 2024

May 15, 2024

BUY
$4.65 - $9.31 $647,326 - $1.3 Million
139,210 Added 1058.23%
152,365 $749,000
Q4 2023

Feb 14, 2024

SELL
$5.81 - $11.2 $1.93 Million - $3.72 Million
-332,303 Reduced 96.19%
13,155 $115,000
Q2 2023

Aug 14, 2023

BUY
$24.7 - $37.61 $5.75 Million - $8.76 Million
232,891 Added 206.89%
345,458 $8.74 Million
Q1 2023

May 15, 2023

SELL
$18.36 - $35.27 $7.07 Million - $13.6 Million
-385,262 Reduced 77.39%
112,567 $3.63 Million
Q4 2022

Feb 14, 2023

BUY
$18.32 - $30.66 $4.67 Million - $7.82 Million
255,146 Added 105.14%
497,829 $9.19 Million
Q3 2022

Nov 14, 2022

SELL
$14.33 - $28.47 $3.26 Million - $6.48 Million
-227,441 Reduced 48.38%
242,683 $6.55 Million
Q2 2022

Aug 15, 2022

BUY
$11.52 - $20.4 $3.88 Million - $6.87 Million
336,645 Added 252.21%
470,124 $6.5 Million
Q1 2022

May 16, 2022

BUY
$12.36 - $20.31 $1.65 Million - $2.71 Million
133,479 New
133,479 $2.6 Million
Q4 2021

Feb 14, 2022

SELL
$12.46 - $27.87 $258,557 - $578,330
-20,751 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$25.78 - $33.21 $534,960 - $689,140
20,751 New
20,751 $578,000
Q2 2021

Aug 16, 2021

SELL
$26.8 - $31.84 $517,186 - $614,448
-19,298 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$24.03 - $29.97 $3 Million - $3.74 Million
-124,707 Reduced 86.6%
19,298 $539,000
Q4 2020

Feb 16, 2021

BUY
$23.41 - $28.34 $3.37 Million - $4.08 Million
144,005 New
144,005 $4.08 Million
Q1 2020

May 14, 2020

SELL
$12.46 - $27.81 $1.36 Million - $3.04 Million
-109,199 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$11.66 - $20.15 $1.27 Million - $2.2 Million
109,199 New
109,199 $1.77 Million
Q2 2019

Aug 14, 2019

SELL
$10.67 - $15.49 $332,455 - $482,637
-31,158 Closed
0 $0
Q1 2019

May 14, 2019

SELL
$15.4 - $20.39 $5.55 Million - $7.35 Million
-360,391 Reduced 92.04%
31,158 $491,000
Q4 2018

Feb 14, 2019

SELL
$18.06 - $24.96 $4.32 Million - $5.97 Million
-239,107 Reduced 37.91%
391,549 $7.88 Million
Q3 2018

Nov 14, 2018

SELL
$23.55 - $30.1 $10.7 Million - $13.6 Million
-452,918 Reduced 41.8%
630,656 $15.7 Million
Q2 2018

Aug 14, 2018

SELL
$27.45 - $33.35 $11.3 Million - $13.7 Million
-410,867 Reduced 27.49%
1,083,574 $29.7 Million
Q1 2018

May 15, 2018

BUY
$29.15 - $37.4 $11.5 Million - $14.8 Million
395,409 Added 35.98%
1,494,441 $46 Million
Q4 2017

Feb 14, 2018

BUY
$24.55 - $36.3 $27 Million - $39.9 Million
1,099,032
1,099,032 $39.3 Million

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.